Medicinal aerosol formulations

• US 5,766,573 A
• Filed: 01/16/1997
• Issued: 06/16/1998
• Est. Priority Date: 12/06/1988
• Status: Expired due to Term

• Current Assignee: 3M Innovative Properties Company (3M Company)
• Original Assignee: Riker Laboratories, Inc. (3M Company)
• Inventors: Greenleaf, David J., Purewal, Tarlochan S.
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Benston, Jr., William E.
• Application Number:
  US08/783,737
• Time in Patent Office: 516 Days
• Field of Search: 424/45, 424/46, 252/305
• US Class Current: 424/45
• CPC Class Codes: A61K 9/008 comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
• CPC Class Codes: A61K 9/124 characterised by the propellant

Abstract

A self-propelling aerosol formulation which may be free from CFC'"'"'s which comprises a medicament, 1,1,1,2-tetrafluoroethane, a surface active agent and at least one compound having a higher polarity than 1,1,1,2-tetrafluoroethane.

Claims

1. In the method of delivering an aerosol formulation containing a medicament from an aerosol container equipped with a metering valve, said formulation being suitable for delivery to the lung by inhalation from said container, the improvement comprising using in said formulation a propellant essentially free of chlorofluorocarbons and comprising 1,1,1,2-tetrafluoroethane.

2. A method according to claim 1, wherein said improvement further comprises the use of a compound selected from the group consisting of ethyl alcohol, isopropyl alcohol, n-pentane, isopentane, neopentane, and isopropyl myristate.

3. A method according to claim 1, wherein said medicament is salbutamol, beclomethasone dipropionate, disodium cromoglycate, pirbuterol, isoprenaline, adrenaline, rimiterol, or ipratropium bromide.